Insights & news

Alex Stratakis participates in a discussion panel on Competition Enforcement post Brexit

  • 27/01/2021
  • News

On 25 January 2021, Van Bael & Bellis partner and head of its London office Alex Stratakis spoke at an online event organised by the British Institute of International and Comparative Law entitled: “Competition Enforcement after Brexit: Agreements, Unilateral Conduct and State Aid”. The panel examined enforcement issues that arise as a result of Brexit in unilateral conduct and State aid enforcement as well as enforcement against anticompetitive agreements. The panel was moderated by Sir Jonathan Faull, Brunswick Group. Other members of the panel included Ann Pope, Competition and Markets Authority, and Joseph Bell, Oxera.

Further details can be found here.

Related insights

Sign up for updates
    • 13/10/2022
    • News

    Distribution across Europe and the UK Verticals regime: Do you really need to mind the “gap”?

    Long awaited developments over the summer provided some appreciable clarity on the refreshed UK distribution regime (following the UK’s withdrawal from the EU). In particular, pursuant to a consultation process that ran almost in parallel to the equivalent EU process, and also adopting the same analytical framework as the EU (see VBB Insights of 27 June 2022), the UK has also now introduced a new verticals agreements block exemption order and accompanying CMA guidance.

    Read more
    • 06/10/2021
    • News

    Alex Stratakis to speak in a panel discussion on Brexit and UK Competition Law

    On 7 October Van Bael & Bellis partner and head of our UK Competition Practice will participate in a panel discussion on "Brexit & Competition law: What Greek/EU lawyers and businesses need to know about the new era of UK competition law". https://lnkd.in/dvyibqgD Other panellists are Dr. Andriani Kalintiri, Lecturer in Competition Law at King's College London. The panel will be moderated by Kyriakos Fountoukakos, Managing Partner, Herbert Smith Freehills in Brussels.

    Read more
    • 19/03/2021
    • Articles

    Brexit - Medicinal Products - Commission Temporarily Redesigns Supply Chains to Cyprus, Ireland, Malta and Northern Ireland

    On 17 March 2021, the Official Journal of the European Union published Commission Delegated Regulation (EU) 2021/457 of 13 January 2021 “amending Delegated Regulation (EU) 2016/161 as regards a derogation from the obligation of wholesalers to decommission the unique identifier of products exported to the United Kingdom” (see, attached copy; the Delegated Regulation). The Delegated Regulation gives effect to a Commission Notice of 23 December 2020 in which the European Commission addressed the issues faced by market operators in Cyprus, Ireland, Malta and Northern Ireland, which are historically dependent on the United Kingdom for their medicine supplies, in complying with the EU’s pharmaceutical acquis following Brexit (see, Van Bael & Bellis Life Sciences News Alert of 23 December 2020). One of the issues identified was that there are currently no importers holding a manufacturing authorisation in Cyprus, Ireland, Malta and Northern Ireland. However, a manufacturing authorisation is required to affix a unique identifier on medicinal products which are imported from outside the EU and placed on the market in the EU. As there are currently no wholesalers in Cyprus, Ireland, Malta and Northern Ireland which can affix a unique identifier on medicinal products that are imported from the United Kingdom, the Delegated Regulation makes it possible for medicinal products which are exported from the EU to the United Kingdom to maintain their initial unique identifier. More precisely, the Delegated Regulation introduces a temporary derogation from the obligation of EU wholesalers to decommission the unique identifier of any medicinal products which they distribute in the United Kingdom. This will facilitate onward distribution of the medicines from the United Kingdom to the cited EU Member States and Northern Ireland. The exemption applies retroactively from 1 January 2021 and will apply until 31 December 2021. The unique identifier was introduced by the Falsified Medicines Directive (Directive 2011/62/EU) with a view to allowing wholesalers and healthcare professionals to verify the authenticity of medicinal products and to identify individual packs.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *